First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

Related Keywords

United States ,American ,Timothyd Henry ,Christian Rommel ,Rogerj Hajjar ,Head Of Research ,American Heart Association Scientific Sessions ,York Heart Association ,Bayer Ag ,Asklepios Biopharmaceutical Inc ,Steering Committee Member ,Asklepios Biopharmaceutical ,Inhibition Therapy ,New York Heart Association ,Principal Investigator ,Steering Committee ,Heart Failure Awareness Week ,Scientific Chair ,Executive Committee ,Pharmaceuticals Division ,Viralgen Vector Core ,Six Minute Walk Test ,Intracoronary Gene Therapy ,Subjects With Non Ischemic ,Accessed February ,Treasure Island ,Statpearls Publishing ,